The deal provides immediate and certain cash value at a premium. Traders should monitor the arbitrage spread, which will narrow as the close approaches. Key risks include regulatory hurdles and potential competing bids, though no go-shop provision suggests a clean path. Look for the definitive proxy statement for detailed terms and voting timeline.
Price Chart
Executive Summary
Catalyst Pharmaceuticals (CPRX) filed additional proxy soliciting materials for its pending acquisition by Angelini Pharma for $31.50 per share in cash, representing a total equity value of approximately $4.1 billion. This all-cash deal offers a 21% premium to the unaffected closing price and a 28% premium to the 30-day VWAP, and has been unanimously approved by Catalyst's board. The transaction is expected to close in Q3 2026, subject to shareholder and regulatory approvals.
Key Facts
- Angelini Pharma acquires Catalyst for $31.50 per share in cash, total equity value ~$4.1 billion
- 21% premium to unaffected closing price on April 22, 2026; 28% premium to 30-day VWAP
- Catalyst Board unanimously approved; received fairness opinion from JP Morgan
- No go-shop provision; termination fee is typical and customary
- Expected close in Q3 2026, subject to shareholder vote and regulatory approvals
Financial Impact
$4.1 billion total equity value; $31.50 per share cash consideration representing 21-28% premium
Risk Factors
- Shareholder approval may face dissident votes; though board is unanimous
- Regulatory approvals, including antitrust clearance, could delay or block the transaction
- Termination fee may deter competing bids but does not eliminate them entirely
- Integration risk for Angelini Pharma as it establishes U.S. commercial presence
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-212474 |
| Document: 0001193125-26-212474-index-headers.html | 0001193125-26-212474 |
| Document: 0001193125-26-212474-index.html | 0001193125-26-212474 |
| Document: 0001193125-26-212474.txt | 0001193125-26-212474 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 22, 2026 5w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 24, 2026 9w ago | 15-12G | $31.49 awaiting T+5 | awaiting T+5 | — | — |
Jul 17, 2026 11w ago | EFFECT | $31.49 $31.49 | · 0.00% | ▼ −0.59% | — |
Jul 15, 2026 11w ago | 25-NSE | $31.49 $31.49 | · 0.00% | ▼ −0.98% | — |
Jul 8, 2026 12w ago | 8-K | $31.47 $31.49 | ▲ +0.06% | ▲ +0.20% | — |
Jun 30, 2026 13w ago | DEFA14A | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
Jun 30, 2026 13w ago | 8-K | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
May 28, 2026 18w ago | PREM14A | $31.23 $31.28 | ▲ +0.16% | ▲ +0.45% | — |
May 12, 2026 20w ago | DEFA14A | $31.14 $31.23 | ▲ +0.29% | ▲ +0.21% | — |
May 11, 2026 20w ago | Press Release | $31.14 $31.23 | ▼ −0.29% | ▼ −0.21% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access